$17.05
0.201.19%
At close: -
$17.05
0.000.00%
After Hours: 4:00 PM EDT
Comments
Loading...
Fulgent Genetics Analyst Ratings and Price Targets | NASDAQ:FLGT | Benzinga
Fulgent Genetics Inc has a consensus price target of $35.25 based on the ratings of 4 analysts. The high is $45 issued by Credit Suisse on March 2, 2023. The low is $16 issued by Piper Sandler on March 4, 2025. The 3 most-recent analyst ratings were released by Piper Sandler on March 4, 2025, November 11, 2024, and March 6, 2024, respectively. With an average price target of $21 between Piper Sandler, there's an implied 23.17% upside for Fulgent Genetics Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Piper Sandler
UBS
Credit Suisse
Raymond James
1calculated from analyst ratings
Analyst Ratings for Fulgent Genetics
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 03/04/2025 | Buy Now | -6.16% | Piper Sandler | David Westenberg60% | $22 → $16 | Maintains | Neutral | Get Alert |
| 11/11/2024 | Buy Now | 29.03% | Piper Sandler | David Westenberg60% | $26 → $22 | Maintains | Neutral | Get Alert |
| 03/06/2024 | Buy Now | 46.63% | Piper Sandler | David Westenberg60% | $28 → $25 | Maintains | Neutral | Get Alert |
| 12/07/2023 | Buy Now | 105.28% | UBS | Dan Leonard55% | → $35 | Initiates | → Neutral | Get Alert |
| 10/16/2023 | Buy Now | 64.22% | Piper Sandler | David Westenberg60% | $37 → $28 | Maintains | Neutral | Get Alert |
| 03/02/2023 | Buy Now | 163.93% | Credit Suisse | Dan Leonard55% | $50 → $45 | Maintains | Outperform | Get Alert |
| 12/08/2022 | Buy Now | 134.6% | Piper Sandler | David Westenberg60% | $65 → $40 | Downgrade | Overweight → Neutral | Get Alert |
| 11/18/2022 | Buy Now | 163.93% | Raymond James | Andrew Cooper54% | → $45 | Initiates | → Outperform | Get Alert |
| 11/14/2022 | Buy Now | 193.26% | Credit Suisse | Dan Leonard55% | $65 → $50 | Maintains | Outperform | Get Alert |
| 11/14/2022 | Buy Now | 281.23% | Piper Sandler | David Westenberg60% | $70 → $65 | Maintains | Overweight | Get Alert |
| 08/25/2022 | Buy Now | 281.23% | Credit Suisse | Dan Leonard55% | → $65 | Initiates | → Outperform | Get Alert |
| 05/16/2022 | Buy Now | 310.56% | Piper Sandler | David Westenberg60% | $85 → $70 | Maintains | Overweight | Get Alert |
FAQ
What is the target price for Fulgent Genetics (FLGT) stock?
The latest price target for Fulgent Genetics (NASDAQ:FLGT) was reported by Piper Sandler on March 4, 2025. The analyst firm set a price target for $16.00 expecting FLGT to fall to within 12 months (a possible -6.16% downside). 2 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Fulgent Genetics (FLGT)?
The latest analyst rating for Fulgent Genetics (NASDAQ:FLGT) was provided by Piper Sandler, and Fulgent Genetics maintained their neutral rating.
When was the last upgrade for Fulgent Genetics (FLGT)?
There is no last upgrade for Fulgent Genetics
When was the last downgrade for Fulgent Genetics (FLGT)?
The last downgrade for Fulgent Genetics Inc happened on December 8, 2022 when Piper Sandler changed their price target from $65 to $40 for Fulgent Genetics Inc.
When is the next analyst rating going to be posted or updated for Fulgent Genetics (FLGT)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Fulgent Genetics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Fulgent Genetics was filed on March 4, 2025 so you should expect the next rating to be made available sometime around March 4, 2026.
Is the Analyst Rating Fulgent Genetics (FLGT) correct?
While ratings are subjective and will change, the latest Fulgent Genetics (FLGT) rating was a maintained with a price target of $22.00 to $16.00. The current price Fulgent Genetics (FLGT) is trading at is $17.05, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.